Ritholtz Wealth Management Boosts Stake in Puma Biotechnology

The investment firm increased its holdings in the biopharmaceutical company by 47.4% during the fourth quarter.

Apr. 12, 2026 at 10:06am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, industrial-looking financial machinery and equipment, conveying a sense of institutional strength and stability without the use of any text or symbols.Ritholtz Wealth Management's increased stake in Puma Biotechnology reflects the investment firm's confidence in the biopharmaceutical company's future growth potential.Los Angeles Today

Ritholtz Wealth Management raised its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 47.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund now owns approximately 694,001 shares of the biopharmaceutical company's stock, worth around $4.1 million.

Why it matters

This significant increase in Ritholtz Wealth Management's position in Puma Biotechnology suggests the investment firm sees potential in the biopharmaceutical company's future prospects. Puma Biotechnology is focused on developing targeted cancer therapies, which is an area of growing interest and investment in the healthcare sector.

The details

According to the filing, Ritholtz Wealth Management acquired an additional 223,234 shares of Puma Biotechnology during the fourth quarter, bringing its total stake to approximately 1.38% of the company's outstanding shares. Puma Biotechnology's lead product is the breast cancer treatment Nerlynx, which received FDA approval in 2017 for extended adjuvant treatment of early-stage HER2-positive breast cancer.

  • Ritholtz Wealth Management filed its most recent 13F report with the SEC in the fourth quarter of 2026.
  • Puma Biotechnology's Nerlynx was approved by the FDA in 2017 for the extended adjuvant treatment of early-stage HER2-positive breast cancer.

The players

Ritholtz Wealth Management

An investment management firm that provides financial planning and investment advisory services to individuals and institutions.

Puma Biotechnology, Inc.

A late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for oncology patients, with its lead product being the breast cancer treatment Nerlynx.

Got photos? Submit your photos here. ›

The takeaway

Ritholtz Wealth Management's increased stake in Puma Biotechnology suggests the investment firm sees long-term potential in the biopharmaceutical company's cancer treatment pipeline, particularly its FDA-approved breast cancer drug Nerlynx. This move highlights the growing investor interest in innovative oncology therapies that address unmet medical needs.